Xin Lang Cai Jing·2025-08-22 07:43Core Viewpoint - Shanghai Pharmaceuticals' subsidiary, Shanghai First Biochemical, has received drug registration certificates for oxytocin injection and octreotide acetate injection in the Philippines, allowing them to enter the market without significant R&D costs [1] Group 1: Product Details - Oxytocin is used for induction of labor and was approved in China in 1994 [1] - Octreotide acetate is used for treating acromegaly and was approved in China in 2006, passing the consistency evaluation for generic drugs in 2022 [1] Group 2: Market Impact - The sales forecast for oxytocin in the Philippines is estimated at $970,000 in 2024 [1] - The approval of these drugs is expected to help expand the company's overseas market presence [1] Group 3: Financial Considerations - The registration costs for these drugs were approximately 50,000 yuan, with no additional R&D expenses incurred [1] - Sales may face uncertainties due to factors such as policy changes and exchange rate fluctuations [1]